Cortese C, Motti C
Department of Internal Medicine, University of Tor Vergata, Rome, Italy.
Public Health Nutr. 2001 Apr;4(2B):493-7. doi: 10.1079/phn2001159.
Homocysteine is an emerging new risk factor for cardiovascular disease. It is a thiol compound derived from methionine and involved in two main metabolic pathways: the cycle of activated methyl groups, requiring folate and vitamin B12 as cofactors, and the transsulfuration pathway to cystathionine and cysteine requiring vitamin B6 as cofactor. The homocysteine metabolism represents an interesting model of gene-environment interaction. Elevations in homocysteine may be caused by genetic defects in enzymes involved in its metabolism or by deficiencies in cofactor levels. A common polymorphism in the gene coding for the 5,10-methylene tetrahydrofolate reductase (MTHFR) (C677T, Ala --> Val) is associated with a decreased activity of the enzyme due to thermolability. In case of homozygosity for the Val allele, a relative deficiency in the remethylation process of homocysteine into methionine leads to a mild-to-moderate hyperhomocysteinemia, a condition recognized as an independent risk factor for atherosclerosis. The genetic influence of the MTHFR polymorphism on homocysteine levels is attenuated in females in premenopausal age and is not significant in subjects who exhibit serum levels of folate and/or vitamin B12 above the 50th percentile of distribution in the general population. The prevalence of the Val/Val genotype varies among different ethnic groups. It is very low in African populations, whereas in Europe and North America it ranges between 5% and 15%. In Italy an even higher prevalence has been reported in some regions. The question whether the MTHFR polymorphism might be per se an independent contributor to cardiovascular risk is debated. The interaction between this or other genetic factors and environmental/nutritional conditions (i.e. intake of vitamins such as folate) is a key determinant for homocysteine concentrations in healthy conditions as well as in some disease (i.e. in renal disorders). Another example of gene/environment interaction in the field of atherosclerosis is given by the apolipoprotein E polymorphism and its influence in response to diet. The presence of a high prevalence of risk-related allelic variants of such candidate genes within a certain population could serve to locally reinforce the recommendations concerning nutrient intake.
同型半胱氨酸是一种新出现的心血管疾病风险因素。它是一种由蛋氨酸衍生而来的硫醇化合物,参与两条主要代谢途径:需要叶酸和维生素B12作为辅助因子的活性甲基循环,以及需要维生素B6作为辅助因子生成胱硫醚和半胱氨酸的转硫途径。同型半胱氨酸代谢代表了一个有趣的基因-环境相互作用模型。同型半胱氨酸水平升高可能是由于参与其代谢的酶的基因缺陷或辅助因子水平不足所致。编码5,10-亚甲基四氢叶酸还原酶(MTHFR)(C677T,丙氨酸→缬氨酸)的基因中的一种常见多态性与该酶因热不稳定性导致的活性降低有关。在缬氨酸等位基因纯合的情况下,同型半胱氨酸再甲基化生成蛋氨酸的过程相对不足会导致轻度至中度高同型半胱氨酸血症,这是一种被认为是动脉粥样硬化独立风险因素的病症。MTHFR多态性对同型半胱氨酸水平的遗传影响在绝经前女性中减弱,在血清叶酸和/或维生素B12水平高于一般人群分布第50百分位数的个体中不显著。缬氨酸/缬氨酸基因型的患病率在不同种族群体中有所不同。在非洲人群中非常低,而在欧洲和北美则在5%至15%之间。在意大利,一些地区报告的患病率甚至更高。MTHFR多态性本身是否可能是心血管风险的独立因素这一问题存在争议。这种或其他遗传因素与环境/营养状况(即叶酸等维生素的摄入)之间的相互作用是健康状况以及某些疾病(如肾脏疾病)中同型半胱氨酸浓度的关键决定因素。动脉粥样硬化领域中基因/环境相互作用的另一个例子是载脂蛋白E多态性及其对饮食反应性的影响。在特定人群中,此类候选基因中与风险相关的等位基因变体的高患病率可能有助于在当地强化有关营养摄入的建议。